Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21263857 | 0.82 | LMNA (0.41) | LMNASLC29A1SMN1; SMN2NT5ERAB9A | |
| SCHEMBL25688724 | 0.81 | SLC29A1 (0.49) | LMNATP53SLC29A1SMN1; SMN2HIF1A | |
| SCHEMBL21263864 | 0.80 | SLC29A1 (0.56) | LMNATP53SLC29A1SMN1; SMN2HIF1A | |
| SCHEMBL25688725 | 0.80 | SLC29A1 (0.39) | LMNASLC29A1SMN1; SMN2RAB9ACYP3A4 | |
| SCHEMBL22349178 | 0.79 | LMNA (0.54) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL5496942 | 0.77 | LMNA (0.66) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL7149377 | 0.75 | LMNA (0.57) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL24444132 | 0.75 | CYP1A2 (0.46) | LMNAALDH1A1SLC29A1SMN1; SMN2RAB9A | |
| SCHEMBL24258662 | 0.75 | SLC29A1 (0.40) | LMNATP53SLC29A1SMN1; SMN2HIF1A | |
| SCHEMBL24258630 | 0.75 | CYP1A2 (0.46) | LMNAALDH1A1SLC29A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694867-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | disclosed |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3752516-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | LMNA 1855/4885ALDH1A1 1444/4885TP53 95/4885 |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | LMNA 2058/4885ALDH1A1 1129/4885TP53 131/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | LMNA 2058/4885ALDH1A1 1129/4885TP53 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.